Clinical Trials Directory

Trials / Terminated

TerminatedNCT01641484

Study of a Predictor for Cervix Cancer

Study Evaluating Predictive Value of Local Control at 19.8 (MRI and TEP Scan) for Patient With Stade I to IIIB Cervix Carcinoma Treated by Radiotherapy

Status
Terminated
Phase
N/A
Study type
Interventional
Enrollment
9 (actual)
Sponsor
Centre Oscar Lambret · Academic / Other
Sex
Female
Age
18 Years – 65 Years
Healthy volunteers
Not accepted

Summary

Non operated cervix cancer are usually treated by radio-chemotherapy. Non control local rate is inexplicably close to 30%. However, important volume of those tumors and their hypoxia degree induce phenomenon of pathologic angiogenesis, explaining these therapeutic failures. Persistence of tumor hypoxia could be a predictive factor of local control

Detailed description

HPV linked cervix cancer is the second most prevalent form of female cancer. It's also the leading cause of death by cancer in Asia, South America and Africa. Hopefully, screening program lead to a 50 % of mortality reduction during the past 40 years. Classic therapeutic strategy consists of external pelvic radiation therapy associated with chemotherapy and followed by brachytherapy. Curative surgical removal is realized 4 to 6 weeks after radiation therapy. However relapse rate is frequent (20 to 30%). Biological mechanisms involved in this high relapse rate are not understood. Nevertheless, it is suggest that initial hypoxia of cervix tumor during 20 Gy radiation therapy is a pejorative prognostic factor. At the opposite, the amelioration of tumor vascularisation during 20 Gy radiation therapy is a positive prognostic factor. It's possible that an amelioration of hypoxia lead to lesser tumor resistance to radiotherapy. However such possibility has to be test during clinical trial. Thus, the objective of ANOXICOL study is to evaluate the predictive value of persistent hypoxia, during 20 Gy radiation therapy associated with chemotherapy, for local control of cervix cancer.

Conditions

Interventions

TypeNameDescription
PROCEDURElocal control at 19.8GyDay 14, full body TEP and pelvis MRI

Timeline

Start date
2012-01-01
Primary completion
2014-12-01
Completion
2015-02-01
First posted
2012-07-16
Last updated
2026-03-13

Locations

1 site across 1 country: France

Source: ClinicalTrials.gov record NCT01641484. Inclusion in this directory is not an endorsement.